CN101002786B - 一种治疗乙型肝炎的贴剂及其制备方法 - Google Patents
一种治疗乙型肝炎的贴剂及其制备方法 Download PDFInfo
- Publication number
- CN101002786B CN101002786B CN2006100010390A CN200610001039A CN101002786B CN 101002786 B CN101002786 B CN 101002786B CN 2006100010390 A CN2006100010390 A CN 2006100010390A CN 200610001039 A CN200610001039 A CN 200610001039A CN 101002786 B CN101002786 B CN 101002786B
- Authority
- CN
- China
- Prior art keywords
- patch
- penetration enhancer
- acid sodium
- vanilloylcatalpol
- amphicoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 26
- 239000011505 plaster Substances 0.000 title description 4
- 239000000758 substrate Substances 0.000 claims abstract description 31
- 239000010410 layer Substances 0.000 claims abstract description 9
- 239000011241 protective layer Substances 0.000 claims abstract description 5
- 239000003961 penetration enhancing agent Substances 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 33
- 239000000178 monomer Substances 0.000 claims description 30
- 229930182478 glucoside Natural products 0.000 claims description 28
- 150000008131 glucosides Chemical class 0.000 claims description 28
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 24
- 229920002125 Sokalan® Polymers 0.000 claims description 24
- 239000011734 sodium Substances 0.000 claims description 24
- 229910052708 sodium Inorganic materials 0.000 claims description 24
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- -1 polypropylene Polymers 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 239000004743 Polypropylene Substances 0.000 claims description 16
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 16
- 229920001155 polypropylene Polymers 0.000 claims description 16
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 12
- 229920002521 macromolecule Polymers 0.000 claims description 12
- 239000004584 polyacrylic acid Substances 0.000 claims description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 12
- 235000009854 Cucurbita moschata Nutrition 0.000 claims description 9
- 235000009852 Cucurbita pepo Nutrition 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000005520 cutting process Methods 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 9
- 238000012856 packing Methods 0.000 claims description 9
- 235000020354 squash Nutrition 0.000 claims description 9
- 235000010603 pastilles Nutrition 0.000 claims description 5
- 229920000728 polyester Polymers 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005977 Ethylene Substances 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 239000005030 aluminium foil Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 240000001980 Cucurbita pepo Species 0.000 claims 1
- JANLDILJJLTVDB-UHFFFAOYSA-N [6-hydroxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-1a-yl]methyl 4-hydroxy-3-methoxybenzoate Chemical compound C1=C(O)C(OC)=CC(C(=O)OCC23C(O2)C(O)C2C3C(OC3C(C(O)C(O)C(CO)O3)O)OC=C2)=C1 JANLDILJJLTVDB-UHFFFAOYSA-N 0.000 abstract description 53
- 239000003814 drug Substances 0.000 abstract description 34
- 239000011159 matrix material Substances 0.000 abstract 2
- AKNILCMFRRDTEY-NUGKWEEESA-N [(1as,1bs,2s,5ar,6s,6as)-1a-(hydroxymethyl)-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bh-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl] 4-hydroxy-3-methoxybenzoate Chemical compound C1=C(O)C(OC)=CC(C(=O)O[C@H]2[C@H]3[C@H]([C@@H](OC=C3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@]3(CO)O[C@H]32)=C1 AKNILCMFRRDTEY-NUGKWEEESA-N 0.000 description 102
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 description 102
- AKNILCMFRRDTEY-UTPSRAKLSA-N COc1cc(ccc1O)C(=O)O[C@@H]1[C@@H]2O[C@]2(CO)C2C1C=CO[C@H]2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound COc1cc(ccc1O)C(=O)O[C@@H]1[C@@H]2O[C@]2(CO)C2C1C=CO[C@H]2O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O AKNILCMFRRDTEY-UTPSRAKLSA-N 0.000 description 51
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 26
- 229940079593 drug Drugs 0.000 description 19
- 238000012360 testing method Methods 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 231100000012 chronic liver injury Toxicity 0.000 description 9
- 240000004244 Cucurbita moschata Species 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 241000700199 Cavia porcellus Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 101710142246 External core antigen Proteins 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229960001866 silicon dioxide Drugs 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 3
- 230000013016 learning Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960001627 lamivudine Drugs 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000195622 Astasia Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004567 concrete Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 剂量(cm<sup>2</sup>/只) | ALT(U/L) | AST(U/L) |
空白对照组模型对照组联苯双酯组 | --150mg/kg | 33.22±4.57619.14±167.14<sup>△△△</sup>367.59±185.78<sup>**</sup> | 101.07±15.42400.58±1 62.65<sup>△△△</sup>135.22±62.02<sup>*</sup> |
组别 | 剂量(cm<sup>2</sup>/只) | AST(U/L) | ALT(U/L) | |
空白对照组模型对照组联苯双酯组 | --150mg/kg | 156.39±18.71709.74±134.46<sup>△△△</sup>401.37±210.23<sup>***</sup> | 51.94±12.00562.09±166.56<sup>△△△</sup>252.37±143.68<sup>***</sup> |
组别 | 剂量(cm<sup>2</sup>/只) | ALT(U/L) | AST(U/L) | |
空白对照组模型对照组联苯双酯组 | --150mg/kg | 59.18±12.90561.94±95.70<sup>△△△</sup>307.26±90.46<sup>***</sup> | 152.76±17.78806.27±115.84<sup>△△△</sup>553.38±133.38<sup>***</sup> |
药物 | 对HBsAg的TI | 对HBeAg的TI |
胡黄连苷II拉米夫定 | 3.25.4 | 3.31.7 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100010390A CN101002786B (zh) | 2006-01-17 | 2006-01-17 | 一种治疗乙型肝炎的贴剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2006100010390A CN101002786B (zh) | 2006-01-17 | 2006-01-17 | 一种治疗乙型肝炎的贴剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101002786A CN101002786A (zh) | 2007-07-25 |
CN101002786B true CN101002786B (zh) | 2010-06-02 |
Family
ID=38702311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100010390A Expired - Fee Related CN101002786B (zh) | 2006-01-17 | 2006-01-17 | 一种治疗乙型肝炎的贴剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101002786B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2606895A1 (en) * | 2010-10-12 | 2013-06-26 | Wuhan University | Transdermal absorption patch of antiviral drug and its preparation method |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101849998B (zh) * | 2009-04-03 | 2013-08-28 | 余向红 | 一种治疗乙型肝炎的敷贴 |
CN101890034B (zh) * | 2009-05-22 | 2014-05-14 | 北京星昊医药股份有限公司 | 一种胡黄连苷ⅱ磷脂组合物及其制备方法 |
CN107441066B (zh) * | 2017-08-09 | 2019-03-15 | 润和生物医药科技(汕头)有限公司 | 一种透皮吸收贴剂及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1298705A (zh) * | 2000-12-19 | 2001-06-13 | 吉林省力源药业股份有限公司 | 治疗乙肝的中药药物及其制备方法 |
CN1468601A (zh) * | 2002-07-19 | 2004-01-21 | 中国医药研究开发中心 | 胡黄连苷ⅱ-一种用于治疗、预防过敏性炎性疾病的新药 |
CN1686201A (zh) * | 2005-03-28 | 2005-10-26 | 拓普中兴(北京)医药科技发展有限公司 | 具有抗乙肝病毒等活性的中药胡黄连提取物及制备方法 |
-
2006
- 2006-01-17 CN CN2006100010390A patent/CN101002786B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1298705A (zh) * | 2000-12-19 | 2001-06-13 | 吉林省力源药业股份有限公司 | 治疗乙肝的中药药物及其制备方法 |
CN1468601A (zh) * | 2002-07-19 | 2004-01-21 | 中国医药研究开发中心 | 胡黄连苷ⅱ-一种用于治疗、预防过敏性炎性疾病的新药 |
CN1686201A (zh) * | 2005-03-28 | 2005-10-26 | 拓普中兴(北京)医药科技发展有限公司 | 具有抗乙肝病毒等活性的中药胡黄连提取物及制备方法 |
Non-Patent Citations (3)
Title |
---|
张强等.药剂学 第1版.北京大学医学出版社,2005,p.568图17-1类型Ⅱ,p.565第33行-p.566第3行,p.574第13-6行,p.575第37行-p.576第3行. |
张强等.药剂学 第1版.北京大学医学出版社,2005,p.568图17-1类型Ⅱ,p.565第33行-p.566第3行,p.574第13-6行,p.575第37行-p.576第3行. * |
权利要求6. |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2606895A1 (en) * | 2010-10-12 | 2013-06-26 | Wuhan University | Transdermal absorption patch of antiviral drug and its preparation method |
EP2606895A4 (en) * | 2010-10-12 | 2014-04-02 | Univ Wuhan | TRANSDERMAL ABSORPTION STAMP OF ANTIVIRAL DRUG AND METHOD FOR PREPARING THE SAME |
Also Published As
Publication number | Publication date |
---|---|
CN101002786A (zh) | 2007-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Megrab et al. | Oestradiol permeation across human skin, silastic and snake skin membranes: the effects of ethanol/water co-solvent systems | |
CN102068474B (zh) | 刺山柑果凝胶膏剂及其生产方法和抗风湿药物的应用 | |
CN101002786B (zh) | 一种治疗乙型肝炎的贴剂及其制备方法 | |
CN101209274B (zh) | 雪莲提取物及其生产方法 | |
CZ2003687A3 (cs) | Způsoby inhibice snížení transdermálního průniku léku inhibicí uzavření transdermální dráhy | |
CN103848875A (zh) | 一种龙胆苦苷原料的制备方法 | |
CN102091111A (zh) | 雪莲巴布剂及其生产方法 | |
CN102579559B (zh) | 一种龙须藤乙酸乙酯提取物、正丁醇提取物及其制备方法和用途 | |
CN100441219C (zh) | 一种伤湿祛痛软膏及其制备方法 | |
CN102875615B (zh) | 大麻药苷a和大麻药总皂苷的提取方法及其应用 | |
CN1701791A (zh) | 一种治疗过敏、变态反应性皮肤病的药物及其制备方法 | |
CN101991585A (zh) | 治疗类风湿性关节炎的透皮吸收涂膜剂及其制备方法 | |
CN101306134A (zh) | 复方南星止痛膏巴布剂组合物及其制备方法 | |
CN107383150B (zh) | 一种具有抗肝损伤活性的化合物及其制备方法和用途 | |
CN103845280B (zh) | 一种20(R)‑人参皂苷Rg3外用制剂、制法与用途 | |
CN1695642A (zh) | 复方土荆皮凝胶及其制备方法 | |
CN101879195A (zh) | 红旱莲有效部位——总黄酮提取物的制备工艺及药物新用途 | |
CN109419823A (zh) | 红豆杉植物提取物及其在制备治疗类风湿性关节炎外用药物中的应用 | |
CN103083677B (zh) | 一种透皮促进剂及其在促透中的应用 | |
CN103933232A (zh) | 一种抗炎镇痛口服制剂及其制备方法和用途 | |
CN102319272A (zh) | 银杏酚酸在制备治疗皮肤病的外用制剂中的用途 | |
CN107019683B (zh) | 一种克班宁透皮贴剂及其制备方法 | |
CN108553639B (zh) | 一种壳聚糖/胰岛素纳米缓释经皮制剂及其制备方法 | |
CN101474230B (zh) | 小飞蓬总黄酮提取物及其制备方法和药物用途 | |
CN110711207A (zh) | 文王一支笔提取物在制备消化道抗溃疡性结肠炎药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIDA SHIJIA TECHNOLOGY DEVELOPMENT CO., LTD. Free format text: FORMER OWNER: ZHOU YAWEI Effective date: 20150119 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150119 Address after: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee after: Beida Shijia Technology Development Co.,Ltd. Address before: 100084, Beijing, Zhongguancun, Haidian District North 123 Avenue, branch office incubator room 2206 Patentee before: Zhou Yawei |
|
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 102206, 20 floor, No. 6, life road, Beijing, Changping District, 3 Patentee after: Beida Shijia Technology Development Co.,Ltd. Address before: 100084 No. 123 North Main Street, Haidian District, Beijing, Zhongguancun Patentee before: Beida Shijia Technology Development Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100602 |
|
CF01 | Termination of patent right due to non-payment of annual fee |